All articles about 上海楼凤FR

International Rugby Day this Saturday in Fort St John

first_imgFor more information, or if you are interested in volunteering, you can email recreation@fortstjohn.ca. FORT ST. JOHN, B.C. – City of Fort St. John Recreation will be celebrating International Rugby Day this Saturday, March 23.In partnership with Engage Sport North, youth between the ages of 6 to 12 will have a chance to learn the basics of rugby for free.According to Recreation, a coach will be on site to teach basic skills and drills of rugby.- Advertisement -If enough players show up, there will be a game of non-contact rugby.It is to note that indoor/clean shoes and a water bottle are required. All other equipment is provided.International Rugby Day is taking place this Saturday, March 23, from 1:30 p.m. to 3:30 p.m. at the Kids Arena Fieldhouse.Advertisementlast_img

Wild Even Series at 1 with Shutout Win12YearOld Struck by Vehicle While

first_imgWenatchee, WA – The Wenatchee Wild rebounded from a disappointing Game 1 loss to fashion a solid 3-0 shutout victory in Game 2 on Sunday night at Town Toyota Center, drawing even at a game apiece in the best-of-seven BCHL Interior Conference Finals against the Vernon Vipers.After a scoreless first period, the Wild took a 1-0 lead on a Jacob Modry snapshot from the blue line, assisted by Matt Gosiewski and Brian Adams at 6:31 of the second. For Modry, it was his third goal of the postseason. In the third period, the Wild converted on a power play to take a 2-0 lead. The Vipers tried to loft the puck out of the zone off the glass but Wild defenseman Brandon Koch was able to glove it and keep it in the zone at the right point, chopping it to Matt Gosiewski who strode to his left and wired a high blocker side wrister at 10:31. PJ Fletcher added a late empty-netter for the 3-0 margin as Austin Park turned aside all 26 shots he faced for his fourth career postseason shutout. It capped a roller coaster week for the Wild netminder who announced his NCAA Division I college commitment to Air Force earlier in the week, then was pulled after a rough start in Game 1 on Saturday, and rebounded with a strong, confident performance on Sunday to help his team even the series at a game apiece.Park’s shutout was the twelfth postseason shutout in Wild history, and sixth since joining the BCHL. His four postseason shutouts ties him with Chase Perry for the franchise record.The best-of-seven heads north to Vernon, BC and Kal Tire Place for Games 3 and 4 on Tuesday and Wednesday, then returns to Town Toyota Center for Game 5 on Friday, April 5. If required, Game 6 is back in Vernon on Sunday April 7 and a potential Game 7 would be played back in Wenatchee on Tuesday April 9.Wenatchee playoff games are available for video streaming on HockeyTV, and will be broadcast live both locally and via internet stream on “NewsRadio 560 KPQ”, with the Pregame Shows starting 15 minutes prior to faceoff.Game recap provided by Arch Ecker and the Wenatchee Wild.last_img read more

FDA grants 510k clearance to market Gynesonics Sonata System

first_imgAug 22 2018Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Sonata® Sonography-Guided Transcervical Fibroid Ablation (Sonata) System.The Sonata System combines a breakthrough integrated technology which is the first and only intrauterine ultrasound system with a proprietary radiofrequency ablation device, providing a transcervical, incision-free, uterus-preserving treatment for uterine fibroids.With an estimated volume of more than 1 million annual global fibroid procedures, Gynesonics projects a $3 billion-4 billion global market opportunity for its Sonata System for the treatment of uterine fibroids, including a market opportunity of more than $1 billion in the U.S. alone.”We are excited to announce FDA clearance of our Sonata System. This is an essential milestone for Gynesonics in our mission to bring this transformational technology for the treatment of uterine fibroids to women,” said President and CEO Christopher Owens. “The patient outcomes achieved with Sonata demonstrate its potential to become a new standard of care in fibroid treatment, providing important patient benefits as compared to invasive surgery. Clinical trial outcomes show that Sonata provides a significant and durable improvement in symptoms with more than half the women returning to normal activities within 24 hours.”In a published survey of 968 women affected by fibroids (American Journal of Obstetrics and Gynecology, 2013), the key findings include:Related StoriesTransobturator sling surgery shows promise for stress urinary incontinenceSleep disorders in patients with low back pain linked to increased healthcare visits, costsApplication of machine learning methods to healthcare outcomes research 79% of women want to avoid invasive surgery; Affected women wait an average of 3.6 years before being treated; Most women, regardless of desire for future fertility, want to preserve their uterus. Source:https://gynesonics.com/ “The published survey results show that women are looking for new options to address this widespread condition, they want to preserve their uterus and they wish to avoid invasive surgery, including hysterectomy,” Owens added. “Sonata is the only system that can treat the vast majority of all fibroids with a transcervical, incision-free, uterus-preserving approach. Current transcervical options are limited to treatment of a small portion of the total fibroid market by comparison.”According to medical literature, about 70-80 percent of women in the U.S. will develop uterine fibroids by age 50, with a significant proportion of women having symptoms, many of which can be severe and debilitating. In addition, according to the New England Journal of Medicine, approximately 200,000 hysterectomies are performed in the United States each year because of symptomatic fibroids.Owens added that the company exceeded the FDA-specified 12-month primary endpoint performance requirements for the Sonata System in the SONATA pivotal IDE clinical trial used to support the FDA regulatory 510(k) filing. The co-primary endpoints included a significant reduction in bleeding and a high rate of freedom from surgical reintervention due to heavy menstrual bleeding (HMB). The safety outcomes were also favorable, including zero device-related adverse events reported in the 147-patient trial.last_img read more